14,363 Shares in XOMA Royalty Corporation $XOMA Bought by Nuveen LLC

Key Points

• Nuveen LLC has invested $286,000 in XOMA Royalty Corporation, acquiring 14,363 shares during the first quarter, bringing its ownership to approximately 0.12% of the company.
• Several institutional investors have significantly increased their stakes in XOMA, with GAMMA Investing LLC's position growing by 1,063.8% in the first quarter.
• XOMA Royalty recently reported an earnings per share (EPS) of $0.48, surpassing estimates by $0.60, and had revenue of $13.13 million for the quarter, above analysts' expectations.

Nuveen LLC acquired a new position in XOMA Royalty Corporation (NASDAQ:XOMA - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 14,363 shares of the biotechnology company's stock, valued at approximately $286,000. Nuveen LLC owned about 0.12% of XOMA Royalty at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of XOMA. GAMMA Investing LLC raised its position in XOMA Royalty by 1,063.8% in the 1st quarter. GAMMA Investing LLC now owns 1,734 shares of the biotechnology company's stock worth $35,000 after purchasing an additional 1,585 shares during the last quarter. Wells Fargo & Company MN raised its position in shares of XOMA Royalty by 38.0% during the 4th quarter. Wells Fargo & Company MN now owns 4,300 shares of the biotechnology company's stock valued at $113,000 after acquiring an additional 1,183 shares during the last quarter. Deutsche Bank AG raised its position in shares of XOMA Royalty by 5,087.9% during the 1st quarter. Deutsche Bank AG now owns 6,433 shares of the biotechnology company's stock valued at $128,000 after acquiring an additional 6,309 shares during the last quarter. Bank of America Corp DE raised its position in shares of XOMA Royalty by 34.7% during the 4th quarter. Bank of America Corp DE now owns 7,796 shares of the biotechnology company's stock valued at $205,000 after acquiring an additional 2,009 shares during the last quarter. Finally, Barclays PLC raised its position in shares of XOMA Royalty by 13.6% during the 4th quarter. Barclays PLC now owns 12,784 shares of the biotechnology company's stock valued at $336,000 after acquiring an additional 1,528 shares during the last quarter. Institutional investors own 95.92% of the company's stock.

XOMA Royalty Trading Up 0.3%

Shares of XOMA traded up $0.11 during trading hours on Monday, reaching $35.35. The stock had a trading volume of 78,135 shares, compared to its average volume of 59,147. The company has a quick ratio of 4.88, a current ratio of 4.88 and a debt-to-equity ratio of 1.41. XOMA Royalty Corporation has a 52 week low of $18.35 and a 52 week high of $36.32. The firm has a 50-day moving average of $29.04 and a 200 day moving average of $25.18. The company has a market cap of $427.38 million, a P/E ratio of -22.81 and a beta of 0.98.

XOMA Royalty (NASDAQ:XOMA - Get Free Report) last released its quarterly earnings data on Wednesday, August 13th. The biotechnology company reported $0.48 EPS for the quarter, beating analysts' consensus estimates of ($0.12) by $0.60. XOMA Royalty had a negative net margin of 27.57% and a positive return on equity of 2.63%. The business had revenue of $13.13 million during the quarter, compared to analysts' expectations of $9.39 million. On average, sell-side analysts expect that XOMA Royalty Corporation will post -1.41 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. HC Wainwright reiterated a "buy" rating and set a $104.00 target price on shares of XOMA Royalty in a research report on Wednesday, May 28th. Zacks Research upgraded shares of XOMA Royalty to a "hold" rating in a research report on Tuesday, August 12th. Finally, Wall Street Zen upgraded shares of XOMA Royalty from a "hold" rating to a "buy" rating in a research report on Monday, August 11th. Two analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $69.50.

About XOMA Royalty

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.